Document Detail


Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
MedLine Citation:
PMID:  12842984     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Fourteen adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) were studied to evaluate the role of imatinib prior to allogeneic stem cell transplantation (SCT). Of these, 12 patients were in complete hematologic response (CHR), and 2 were refractory. Imatinib was administered as an interim schedule after each chemotherapy course. After the first imatinib cycle, 11 patients remained in sustained CHR with a decrease in the BCR-ABL/ABL ratios (0.89 logs), and one refractory patient achieved CHR. Meanwhile, 2 patients were resistant to imatinib. Ten patients receiving a second imatinib cycle following consolidation showed sustained CHR, including 2 molecular CR, with a further decrease in the BCR-ABL/ABL ratios (0.19 logs). Twelve patients underwent SCT in a favorable status, and of these, 11 are still alive in a leukemia-free status at 9 to 28+ months after SCT. First-line imatinib interim therapy appears to be a useful strategy to bridge the time to SCT for patients with Ph+ ALL.
Authors:
Seok Lee; Dong-Wook Kim; Yoo-Jin Kim; Nak-Gyun Chung; Yoo-Li Kim; Ji-Yeon Hwang; Chun-Choo Kim
Related Documents :
15607364 - Bone marrow cd34+ cell count is predictive for adequate peripheral progenitor cell coll...
8141124 - Treatment of refractory undifferentiated acute myelogenous leukemia with all-trans-reti...
3660194 - Splenectomy performed upon thirty-seven patients with hairy cell leukemia.
3259934 - Calcitonin-related peptides in patients with acute leukemia: association of human calci...
3979134 - Gas exchange alterations in patients with chronic obstructive lung disease.
16847234 - Safety of prolonged intermittent pringle maneuver during hepatic resection.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2003-07-03
Journal Detail:
Title:  Blood     Volume:  102     ISSN:  0006-4971     ISO Abbreviation:  Blood     Publication Date:  2003 Oct 
Date Detail:
Created Date:  2003-10-06     Completed Date:  2003-11-24     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7603509     Medline TA:  Blood     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3068-70     Citation Subset:  AIM; IM    
Affiliation:
Catholic Hematopoietic Stem Cell Transplantation Center, College of Medicine, The Catholic University of Korea, Seoul. leeseok@catholic.ac.kr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antineoplastic Agents / therapeutic use*
Disease Progression
Female
Fusion Proteins, bcr-abl / biosynthesis
Humans
Karyotyping
Kinetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
Male
Middle Aged
Piperazines / therapeutic use*
Polymerase Chain Reaction
Pyrimidines / therapeutic use*
RNA / metabolism
RNA, Messenger / metabolism
Reverse Transcriptase Polymerase Chain Reaction
Risk
Stem Cell Transplantation / methods*
Time Factors
Transplantation, Homologous / methods*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Fusion Proteins, bcr-abl; 0/Piperazines; 0/Pyrimidines; 0/RNA, Messenger; 152459-95-5/imatinib; 63231-63-0/RNA

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  TGF-beta signaling-deficient hematopoietic stem cells have normal self-renewal and regenerative abil...
Next Document:  Tec regulates platelet activation by GPVI in the absence of Btk.